Bilirubin-to-Albumin Ratio: Clinical Decision Tool for Jaundice Treatment
Introduction: Beyond Total Serum Bilirubin
Total serum bilirubin (TSB) has been the cornerstone of neonatal jaundice management for decades, with well-established nomograms (Bhutani, AAP, NNF) guiding phototherapy and exchange transfusion decisions. However, TSB alone does not directly measure the neurotoxic fraction of bilirubin—the unbound (free) bilirubin that can cross the blood-brain barrier and cause acute bilirubin encephalopathy (ABE) and kernicterus.
The bilirubin-to-albumin (B/A) ratio serves as a practical clinical surrogate for free bilirubin estimation. Because albumin is the primary bilirubin-binding protein in plasma, the ratio of bilirubin to albumin provides insight into binding saturation and, by extension, the likelihood of free bilirubin accumulation. The AAP endorsed the B/A ratio in its 2004 guidelines (reaffirmed 2022) as an additional tool for identifying neonates who may benefit from exchange transfusion.
Physiology of Bilirubin-Albumin Binding
Binding Characteristics
Each albumin molecule has one high-affinity primary binding site for unconjugated bilirubin and several low-affinity secondary sites. The binding is characterized by:
- Association constant (Ka): Approximately 10⁷ L/mol at the primary site under physiological conditions
- Molar binding ratio: 1:1 at the primary site (1 mol albumin binds 1 mol bilirubin)
- Mass binding ratio: 1 gram of albumin binds approximately 8.5 mg of bilirubin
- Saturation threshold: When bilirubin exceeds the primary binding capacity, low-affinity sites and free bilirubin increase rapidly
Factors That Reduce Binding Affinity
| Factor | Mechanism | Clinical Implication |
|---|---|---|
| Acidosis (pH less than 7.2) | Conformational change in albumin | Lower B/A threshold for exchange |
| Hypothermia | Reduced binding affinity | Monitor temperature closely |
| Drug displacement | Competitive binding at primary site | Avoid sulfonamides, ceftriaxone |
| Free fatty acids | Compete for albumin binding | Common in sick/stressed neonates |
| Prematurity | Lower albumin levels + reduced affinity | Use lower B/A thresholds |
| Sepsis/inflammation | Altered albumin structure | B/A ratio may underestimate risk |
| Hypoalbuminemia | Fewer binding sites available | High B/A ratio at lower TSB levels |
Calculating the B/A Ratio
Formula and Units
The B/A ratio is calculated as:
B/A Ratio = Total Serum Bilirubin (mg/dL) ÷ Serum Albumin (g/dL)
Result expressed as mg/g (or equivalently, mg bilirubin per g albumin)
For SI units: B/A Ratio (µmol/g) = B/A Ratio (mg/g) × 17.1
Example Calculations
| TSB (mg/dL) | Albumin (g/dL) | B/A Ratio (mg/g) | Risk Level (Term) |
|---|---|---|---|
| 18 | 3.5 | 5.1 | Low—phototherapy adequate |
| 22 | 3.0 | 7.3 | Moderate—intensive phototherapy, consider exchange |
| 20 | 2.5 | 8.0 | High—exchange transfusion threshold reached |
| 25 | 3.0 | 8.3 | Critical—exchange transfusion indicated |
| 16 | 2.0 | 8.0 | High risk despite lower TSB—consider exchange |
The last example illustrates the value of B/A ratio: a TSB of 16 mg/dL would normally not trigger exchange transfusion consideration, but with albumin of only 2.0 g/dL, the binding capacity is severely compromised and free bilirubin may be dangerously elevated.
AAP Recommended B/A Ratio Thresholds
| Risk Category | Gestational Age | B/A Ratio Threshold (mg/g) | B/A Ratio Threshold (µmol/g) |
|---|---|---|---|
| Lower risk | ≥38 weeks, healthy | 8.0 | 136.8 |
| Medium risk | ≥38 weeks with risk factors, or 35-37+6 weeks healthy | 7.2 | 123.1 |
| Higher risk | 35-37+6 weeks with risk factors | 6.8 | 116.3 |
Risk factors include: isoimmune hemolytic disease, G6PD deficiency, asphyxia, sepsis, significant lethargy, temperature instability, and acidosis.
AAP Position: The B/A ratio should be used in conjunction with, not as a replacement for, TSB levels and the hour-specific nomogram. When either TSB or B/A ratio reaches the exchange transfusion threshold, exchange should be considered.
Clinical Application in Indian Practice
NNF India Approach
The NNF acknowledges the B/A ratio as a useful adjunctive tool and recommends:
- Measuring serum albumin in all neonates with TSB approaching phototherapy or exchange thresholds
- Calculating B/A ratio when albumin is less than 3.0 g/dL
- Using B/A ratio thresholds alongside TSB-based nomograms for exchange transfusion decisions
- Considering albumin infusion when B/A ratio exceeds critical thresholds (see albumin protocol)
Practical Challenges in India
- Albumin measurement availability: While serum albumin is a routine biochemistry test available at most hospitals, point-of-care albumin testing is not yet widespread in Indian primary health centers
- Cost: Serum albumin test costs INR 100-300—affordable but adds to the workup cost for families
- Laboratory turnaround: In busy government hospitals, albumin results may take 4-8 hours, limiting real-time B/A ratio calculation
- Awareness: Many clinicians rely solely on TSB without considering albumin status; education and protocol integration are needed
When B/A Ratio Changes Management
The B/A ratio is most clinically valuable in the following scenarios:
- Preterm neonates: Lower albumin levels mean higher B/A ratios at any given TSB. A preterm infant at 33 weeks with TSB 15 mg/dL and albumin 2.0 g/dL has a B/A ratio of 7.5—already approaching the exchange threshold
- Hypoalbuminemic neonates: From sepsis, SGA status, liver disease, or prolonged parenteral nutrition
- Drug displacement situations: When bilirubin-displacing drugs (sulfonamides, ceftriaxone) are being administered, the effective B/A ratio is worse than calculated
- Neonates with multiple risk factors: Acidosis + sepsis + hypoalbuminemia—B/A ratio captures cumulative risk better than TSB alone
Integration with Phototherapy Decision-Making
While B/A ratio thresholds are primarily described for exchange transfusion decisions, they also inform phototherapy intensity decisions:
| B/A Ratio Range (mg/g, term) | Clinical Action |
|---|---|
| Less than 5.0 | Standard phototherapy if TSB warrants; routine monitoring |
| 5.0-7.0 | Intensive phototherapy; consider albumin if albumin less than 2.5 g/dL |
| 7.0-8.0 | Intensive phototherapy; prepare for exchange; consider IVIG and albumin |
| Greater than 8.0 | Exchange transfusion indicated; albumin infusion pre-exchange |
Effective phototherapy using high-irradiance LED units—available through HEAMAC phototherapy rental—is the primary intervention at all B/A ratio levels below the exchange threshold. Even at elevated B/A ratios, intensive phototherapy may stabilize or reduce bilirubin while exchange transfusion is being prepared.
Free Bilirubin Measurement: The Gold Standard
Direct Free Bilirubin Measurement
While B/A ratio is a practical estimate, direct measurement of unbound (free) bilirubin (Bf) by the peroxidase method (UnaG or modified peroxidase assay) provides the most accurate assessment of neurotoxicity risk. However, this test is available only in research settings and select tertiary centers worldwide; it is not routinely available in Indian hospitals. The B/A ratio remains the best clinically available surrogate.
Emerging Technologies
Point-of-care Bf measurement devices are in development and may eventually replace both TSB and B/A ratio as the primary decision tool. Until then, the combination of hour-specific TSB nomogram and B/A ratio provides the best clinically practical approach to jaundice treatment decisions.
Summary: Practical Protocol for Indian NICUs
- Measure serum albumin in all neonates with TSB greater than 15 mg/dL (term) or greater than 10 mg/dL (preterm)
- Calculate B/A ratio for every neonate being evaluated for exchange transfusion
- Use B/A ratio thresholds alongside TSB thresholds—exchange transfusion is indicated if either threshold is exceeded
- Consider albumin infusion (1 g/kg IV) when B/A ratio exceeds 7.0 mg/g with TSB approaching exchange levels
- Initiate intensive phototherapy at lower TSB levels when albumin is low (less than 2.5 g/dL)
- Document B/A ratio in the medical record as part of the jaundice management flowsheet
- Ensure intensive phototherapy is always running while assessing B/A ratio—HEAMAC phototherapy rental ensures continuous high-irradiance LED therapy
Key Message: The B/A ratio is a simple, inexpensive clinical tool that adds significant value to neonatal jaundice management. It is particularly important in preterm and sick neonates where hypoalbuminemia is common and TSB alone may underestimate neurotoxicity risk. Every Indian NICU should incorporate B/A ratio into their standard jaundice assessment protocol.